Aandeel SONN SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Sonnet BioTherapeutics Holdings, Inc.

Aandelen

SONN

US83548R3030

Beurs gesloten - Nasdaq
Andere beurzen
 22:30:01 26-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,9319 USD +1,29% Intraday-grafiek van Sonnet BioTherapeutics Holdings, Inc. -39,09% -46,44%
20/06 Top Middag Decliners MT
13/06 Sonnet BioTherapeutics Holdings, Inc. Kondigt de ontwikkeling en karakterisering aan van twee nieuwe immunotherapeutische pijplijnmedicijnkandidaten, SON-1411 en SON-1400, die elk een variante IL-18 domein bevatten CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!
Gratis inschrijven
Top Midday Decliners
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
Sonnet BioTherapeutics Holdings, Inc. Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Sonnet BioTherapeutics Holdings, Inc. Announces Review of Strategic Alternatives
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics : Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Form 8-K
Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy at the AACR 2024 Annual Meeting
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street
Top Premarket Gainers
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers SONN
  4. Nieuws Sonnet BioTherapeutics Holdings, Inc.
  5. Andere talen